Morgan Stanley Cautious on Sarepta Despite CEO Change

Morgan Stanley views Sarepta Therapeutics' CEO transition as positive.

The investment firm remains cautious in the near term due to Duchenne muscular dystrophy business challenges.

The analysis focuses on SRPT stock performance and outlook.

Morgan Stanley's stance reflects mixed signals from the company's pipeline and market conditions.